These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 15215148

  • 1. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y, Sunagawa M.
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [Abstract] [Full Text] [Related]

  • 13. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP, Mingoia M, Varaldo PE.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [Abstract] [Full Text] [Related]

  • 14. Synergy and mechanism of interaction between pefloxacin and penicillin G against enterococci.
    Grossato A, Fontana R.
    New Microbiol; 1997 Jul; 20(3):221-5. PubMed ID: 9258941
    [Abstract] [Full Text] [Related]

  • 15. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH.
    Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
    [Abstract] [Full Text] [Related]

  • 16. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ, Fraise AP, Andrews JM, Jevons G, Brenwald NP, Wise R.
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [Abstract] [Full Text] [Related]

  • 17. In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.
    Fujikawa K, Chiba M, Tanaka M, Sato K.
    Antimicrob Agents Chemother; 2005 Jul; 49(7):3040-5. PubMed ID: 15980395
    [Abstract] [Full Text] [Related]

  • 18. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV.
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [Abstract] [Full Text] [Related]

  • 19. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L.
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [Abstract] [Full Text] [Related]

  • 20. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ.
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.